201 HASKINS WAY, SOUTH SAN FRANCISCO, CA
Market cap: $36.5M (2/13/2024)
Price: $5.85
Clinical Trial of CER-1236 CAR-T Therapy for High-Risk MDS/AML
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
CERo Therapeutics Update on CER-1236 Phase 1 Trial in AML
Stockholders Approve Amendment to CERo Therapeutics 2024 Equity Incentive Plan
Cero Therapeutics Enters $25 Million Common Stock Purchase Agreement
Announces Receipt of Nasdaq Panel Determination
Cero Therapeutics Enters SPA Amendment to Increase Initial Closing by $500,000
Cero Therapeutics Enters $7 Million Securities Purchase Agreement
Q3
Notice of Late Filing for Quarterly Report
Q2
Q1
Amended Annual Report
FY 2024
Notice of Late Filing for Annual Report
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
PRER14A
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Definitive Revised Proxy Statement
Correspondence